Tags

Type your tag names separated by a space and hit enter

The truth about oral contraceptives and venous thromboembolism.
J Reprod Med. 2003 Nov; 48(11 Suppl):930-8.JR

Abstract

In the last decade, the contribution of the progestin component of oral contraceptives (OCs) to the risk of venous thromboembolism (VTE) has come under scrutiny. The publication of 4 papers in late 1995 and early 1996 led to many women discontinuing OCs containing desogestrel and gastodene, the so-called third-generation OCs. This "pill scare" was the result of study findings that the third-generation OCs were associated with a higher risk of VTE than were OCs containing older progestins, primarily levonorgestrel. Subsequent studies and reanalysis of the original studies have not provided a definitive answer to this continuing debate. More recently, a question was raised about a possible increase in the risk of VTE associated with the use of an OC containing the novel progestin drospirenone. However, the information to date does not support any increase in the risk of VTE with use of the drospirenone-containing OC as compared with any other combination OC.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, 333 East Superior Street, Suite 484, Chicago, IL 60611-3095, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

14686030

Citation

Shulman, Lee P., and Joseph W. Goldzieher. "The Truth About Oral Contraceptives and Venous Thromboembolism." The Journal of Reproductive Medicine, vol. 48, no. 11 Suppl, 2003, pp. 930-8.
Shulman LP, Goldzieher JW. The truth about oral contraceptives and venous thromboembolism. J Reprod Med. 2003;48(11 Suppl):930-8.
Shulman, L. P., & Goldzieher, J. W. (2003). The truth about oral contraceptives and venous thromboembolism. The Journal of Reproductive Medicine, 48(11 Suppl), 930-8.
Shulman LP, Goldzieher JW. The Truth About Oral Contraceptives and Venous Thromboembolism. J Reprod Med. 2003;48(11 Suppl):930-8. PubMed PMID: 14686030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The truth about oral contraceptives and venous thromboembolism. AU - Shulman,Lee P, AU - Goldzieher,Joseph W, PY - 2003/12/23/pubmed PY - 2004/4/3/medline PY - 2003/12/23/entrez SP - 930 EP - 8 JF - The Journal of reproductive medicine JO - J Reprod Med VL - 48 IS - 11 Suppl N2 - In the last decade, the contribution of the progestin component of oral contraceptives (OCs) to the risk of venous thromboembolism (VTE) has come under scrutiny. The publication of 4 papers in late 1995 and early 1996 led to many women discontinuing OCs containing desogestrel and gastodene, the so-called third-generation OCs. This "pill scare" was the result of study findings that the third-generation OCs were associated with a higher risk of VTE than were OCs containing older progestins, primarily levonorgestrel. Subsequent studies and reanalysis of the original studies have not provided a definitive answer to this continuing debate. More recently, a question was raised about a possible increase in the risk of VTE associated with the use of an OC containing the novel progestin drospirenone. However, the information to date does not support any increase in the risk of VTE with use of the drospirenone-containing OC as compared with any other combination OC. SN - 0024-7758 UR - https://www.unboundmedicine.com/medline/citation/14686030/The_truth_about_oral_contraceptives_and_venous_thromboembolism_ L2 - https://medlineplus.gov/deepveinthrombosis.html DB - PRIME DP - Unbound Medicine ER -